Vaxcyte announced positive topline results from its OPUS-1 Phase 3 trial for VAX-31, a pneumococcal vaccine candidate, meeting all primary endpoints. This successful trial significantly de-risks the development of VAX-31 and positions Vaxcyte as a strong contender in the pneumococcal vaccine market, potentially impacting competitors.
Vaxcyte reported that its VAX-31 pneumococcal conjugate vaccine candidate met all prespecified primary endpoints in the OPUS-1 pivotal adult Phase 3 trial. This includes noninferiority to Prevnar 20 (PCV20) and Capvaxive (PCV21) for shared serotypes, and superiority for unique VAX-31 serotypes. This is a critical milestone for Vaxcyte, validating its carrier-sparing platform and paving the way for a Biologics License Application submission in the first half of 2028. For traders, this represents a significant long-term opportunity for Vaxcyte (PCVX) as it enters a lucrative market, while posing a competitive threat to established players like Pfizer (PFE) and Moderna (MRNA) in the short to medium term as VAX-31 progresses towards commercialization.